Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (3,553,162)	$ (1,828,715)
Loss from discontinued operations, net of tax	(1,252,276)
Gain on sale of discontinued operations	1,534,479
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations	(1,534,479)
Stock-based compensation	211,469	180,509
Depreciation and amortization of intangible assets	23,531	24,101
Amortization of right of use assets	34,039	35,809
Amortization of debt discount	13,468	703
Change in fair value of forward purchase agreement	2,156,837
Change in fair value of derivative liabilities		325,085
Changes in operating assets and liabilities:
Prepaid expenses	229,944	47,826
Assets available for sale	4,662,980
Other current assets	(17,563)	11,183
Accounts payable	(133,764)	159,097
Accrued expenses and other liabilities	(1,027,089)	337,258
Lease liability	(34,849)	(31,413)
Accrued interest		262,598
Liabilities available for sale	(2,389,343)
Net cash used in operating activities	(1,075,778)	(475,959)
Cash flows from investing activities
Cash paid in AxoBio Disposition	(748,796)
Net cash used in investing activities	(748,796)
Cash Flows from Financing Activities:
Proceeds from issuance of loans and related warrants	31,538	375,000
Payment of loans	(227,264)
Net cash (used in) provided by financing activities	(195,726)	375,000
Net decrease in cash	(2,020,300)	(100,959)
Cash - beginning of the period	2,912,461	128,149
Cash - end of the period	892,161	27,190
Supplemental cash flow information:
Interest paid	11,566	37,037
Non-cash financing activity:
Net assets sold in AxoBio Acquisition	21,921,697
Fair value of shares received in AxoBio Disposition	23,456,179
Common Stock issued in connection with conversion of Promissory Notes	$ 375,000
Accrued Legacy Series A preferred stock dividends		75,084
Accrued Legacy Series C-1 preferred stock dividends		18,716
Accrued Legacy Series C-2 preferred stock dividends		217,368
Warrants issued in connection with convertible notes		6,112
Unpaid deferred offering costs		$ 660,426